ESMO Virtual 2020: Quality of life impact of immune checkpoint inhibitors
Immune checkpoint inhibitors have changed the way renal cell carcinoma [...]
Burnout among cancer professionals during COVID-19
Two online surveys presented at the European Society of Medical [...]
Biomarkers for avelumab plus axitinib in advanced kidney cancer
The discovery of a reliable biomarker for how patients with [...]
The significance of body mass index (BMI) on kidney cancer outcomes
Being overweight or obese is a well-known risk factor for [...]
Triggers for delayed treatment in patients with small renal masses undergoing active surveillance
Active surveillance is an acceptable management strategy for patients with [...]
How the coronavirus pandemic may affect cancer clinical trials
In this article published in Cancer Therapy Advisor this week, [...]
ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients
In a paper presented at this year’s European Society of [...]
ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer
Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were [...]
ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
